Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06477952 · ClinicalTrials.gov registry record · Phase 1

DRonabinol Treatment of OSA

A Phase 1 study of Obstructive Sleep Apnea, sponsored by VA Office of Research and Development.

Recruiting
Registry status
Phase 1
Development phase
120
Enrollment target
1
Study location

NCT06477952 is a Phase 1 study of Obstructive Sleep Apnea that is actively recruiting participants, run by VA Office of Research and Development. The registered enrollment target is 120 participants, below the 221-participant average among 155 other Obstructive Sleep Apnea trials with a reported enrollment target (46% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06477952, a Phase 1 study of Obstructive Sleep Apnea, is actively recruiting participants, sponsored by VA Office of Research and Development.

RECRUITING
Registry status
Phase 1
Development phase
120 participants
Enrollment target
1
Study location

Study Summary

This is an open-label trial that tests the effectiveness of Dronabinol in treating obstructive sleep apnea (OSA). All participants will take oral Dronabinol for two weeks. Sleep studies will be conducted before and after treatment to measure OSA severity.

Conditions Studied

Interventions

  • DRUG Dronabinol

Study Locations (1)

Illinois

  • Jesse Brown VA Medical Center, Chicago, IL - Chicago

Trial Details

FieldValue
Enrollment Target 120 participants
Start Date 2025-08-25
Est. Completion 2026-12-31
Phase Phase 1

Sponsor

VA Office of Research and Development

1,668 total trials

What the Registry Record Tells You About NCT06477952

The ClinicalTrials.gov registry entry for NCT06477952 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 221-participant average among 155 other Obstructive Sleep Apnea trials with a reported enrollment target (46% lower). The listed sponsor is VA Office of Research and Development, which has 1,668 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Obstructive Sleep Apnea appearing as the primary indexed condition, and to 1 intervention - of which Dronabinol is the first listed.

NCT06477952 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.

Frequently Asked Questions

What is clinical trial NCT06477952 about?

NCT06477952 is a clinical study titled "DRonabinol Treatment of OSA". This is an open-label trial that tests the effectiveness of Dronabinol in treating obstructive sleep apnea (OSA). All participants will take oral Dronabinol for two weeks. Sleep studies will be conducted before and after treatment to measure OSA severity.

What is the current status of trial NCT06477952?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 120 participants. The study started on 2025-08-25. Estimated completion is 2026-12-31.

What conditions does trial NCT06477952 study?

This clinical trial studies the following conditions: Obstructive Sleep Apnea.

What interventions are being tested in trial NCT06477952?

The interventions under investigation include: Dronabinol (DRUG).

Who is sponsoring clinical trial NCT06477952?

This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06477952 being conducted?

This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Obstructive Sleep Apnea

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.